What it's for (Indications)
- This fixed-dose combination medication, containing tamsulosin hydrochloride and solifenacin succinate, is indicated for the treatment of signs and symptoms associated with benign prostatic hyperplasia (BPH) in adult men who also experience overactive bladder (OAB) symptoms such as urinary urgency, increased micturition frequency, and urgency incontinence.
- It is intended for patients whose symptoms are inadequately controlled by monotherapy with either an alpha1-adrenoceptor antagonist or an antimuscarinic agent alone.
- The combination aims to simultaneously alleviate bladder outlet obstruction symptoms and bothersome storage symptoms, offering a comprehensive approach to managing complex lower urinary tract symptoms in men with both conditions.
- Diagnosis of BPH and OAB should be confirmed before initiating therapy, and other potential causes of urinary symptoms must be ruled out.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical recommended dosage for this combination therapy is one tablet orally once daily, administered with or shortly after a meal, at approximately the same time each day. The exact strength may vary, but common formulations combine tamsulosin 0.4 mg with solifenacin 6 mg or 9 mg. Dosage adjustments may be necessary in patients with moderate renal or hepatic impairment, and caution is advised. For patients with severe renal or hepatic impairment, or those concurrently taking potent CYP3A4 inhibitors, lower doses of the solifenacin component may be required, or the combination may be contraindicated. It is crucial to swallow the tablet whole with liquid; it should not be chewed, crushed, or split, as this can affect the controlled release of the components. Adherence to prescribed dosing is essential for efficacy and safety. |
Safety & Warnings
Common Side Effects
- Common adverse reactions associated with tamsulosin HCl and solifenacin succinate combination therapy include, but are not limited to, dry mouth, constipation, blurred vision, dizziness, somnolence, abnormal ejaculation (e.
- g.
- , retrograde ejaculation, anejaculation), and orthostatic hypotension.
- Other potential side effects include nausea, dyspepsia, fatigue, headache, urinary tract infection, and peripheral edema.
- Less common but more serious adverse events can involve acute urinary retention, particularly in patients with severe bladder outlet obstruction; allergic reactions such as rash, pruritus, or angioedema; and CNS effects including hallucinations or confusion, particularly in elderly patients.
- Patients should be advised to report any persistent or worsening side effects to their healthcare provider.
- Due to the potential for dizziness and orthostatic hypotension, caution is advised when performing tasks requiring mental alertness, such as driving or operating machinery.
Serious Warnings
- Black Box Warning: Serious Warnings: This combination medication does not carry an FDA-mandated Black Box Warning. However, prescribers and patients must be aware of several serious safety concerns. Alpha1-adrenoceptor antagonists, including tamsulosin, can cause significant orthostatic hypotension, leading to dizziness, lightheadedness, and syncope, particularly upon initiation of therapy or dosage escalation. Patients should be advised to avoid situations where injury could result from syncope. Additionally, Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in patients treated with alpha1-adrenoceptor antagonists; ophthalmologists should be informed of current or past use. The solifenacin component carries a risk of acute urinary retention, especially in patients with clinically significant bladder outlet obstruction. Anticholinergic effects such as heat prostration in warm environments, blurred vision, and cognitive impairment (especially in the elderly) warrant careful consideration. Rarely, severe allergic reactions, including angioedema, have been reported. Immediate medical attention is required for any signs of allergic reaction or priapism (prolonged erection).
- Prior to initiating therapy, it is imperative to rule out the presence of prostate carcinoma, as BPH and prostate cancer can coexist and present with similar symptoms.
- Patients should be counselled about the risk of orthostatic hypotension, which can manifest as dizziness, lightheadedness, or syncope, especially upon standing quickly or during the initiation of therapy.
- Caution is advised when engaging in activities requiring mental alertness.
- Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery in patients treated with alpha1-adrenoceptor antagonists, including tamsulosin; ophthalmic surgeons should be informed of current or past tamsulosin use.
- Acute urinary retention can be precipitated or worsened, particularly in patients with pre-existing severe bladder outlet obstruction or compromised bladder function.
- Anticholinergic effects, such as heat prostration in warm environments or impaired cognitive function (especially in the elderly), are possible due to the solifenacin component.
- This medication should be used with caution in patients with a history of QT prolongation or those taking medications known to prolong the QT interval.
How it Works (Mechanism of Action)
This combination medication leverages two distinct pharmacological mechanisms to address complex lower urinary tract symptoms. Tamsulosin hydrochloride is an alpha1A-adrenoceptor antagonist that selectively and competitively blocks alpha1A-adrenergic receptors, predominantly located in the smooth muscle of the prostate, prostatic capsule, bladder neck, and prostatic urethra. This blockade leads to relaxation of these smooth muscles, thereby decreasing bladder outlet obstruction and improving urinary flow symptoms associated with benign prostatic hyperplasia. Solifenacin succinate is a competitive muscarinic receptor antagonist, primarily acting on the M3 muscarinic receptors found in the bladder. By blocking these receptors, solifenacin inhibits involuntary detrusor muscle contractions, reducing symptoms of overactive bladder such as urgency, frequency, and urge incontinence. The synergistic action of relaxing the bladder outlet and reducing bladder hyperactivity provides comprehensive symptomatic relief for men suffering from both BPH and OAB.
Commercial Brands (Alternatives)
No other brands found for this formula.